press release

May 5, 2017

Alnylam Pharmaceuticals Reports Second Quarter 2007 Financial ResultsCAMBRIDGE, Mass. (BUSINESS WIRE) Aug. 9, 2007 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter of 2007, company highlights, and an update on cash guidance and pipeline goals. "The first half of 2007 has been game changing for Alnylam. The formation of ...

press release

May 5, 2017

Alnylam Grants GeneDesign License to Kreutzer Limmer Patents for the RNA Interference (RNAi) Research Products MarketCAMBRIDGE, Mass. and OSAKA, Japan (BUSINESS WIRE) Oct. 3, 2007 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and GeneDesign, Inc., announced today that Alnylam has granted GeneDesign a non exclusive license to provide RNAi research products and services under the Kreutzer Limmer patent ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Fourth Quarter and Year End 2005 Financial ResultsCAMBRIDGE, Mass. (BUSINESS WIRE) Feb. 15, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY): Company Enters Clinical Stage and Forms Significant Pharmaceutical Alliances Maintains Leadership Position for RNAi Therapeutics in Science, Product Pipeline, Intellectual Property, and Business Execution Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial ...

press release

May 5, 2017

Alnylam and Collaborators Present Pre Clinical Data for RNAi Therapeutics for the Treatment of Respiratory Diseases Including Pandemic Influenza; Results Include Data on Anti viral Activity of RNAi Therapeutics toward H5N1 VirusCAMBRIDGE, Mass. (BUSINESS WIRE) May 23, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it presented pre clinical data at the American Thoracic Society ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports First Quarter 2006 Financial Results; Company Achieves Multiple Milestones and Recognizes Increased Revenue from Pharmaceutical PartnersCAMBRIDGE, Mass. (BUSINESS WIRE) May 9, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter ended March 31, 2006 and company highlights. "We have made considerable progress on multiple fronts since the ...

press release

May 5, 2017

Alnylam Announces Collaboration with University of Texas Southwestern Medical Center to Discover RNAi Therapeutics for Hypercholesterolemia; Collaboration to Focus on PCSK9, a Key Gene Involved in Metabolism of LDL CholesterolCAMBRIDGE, Mass. (BUSINESS WIRE) July 17, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has entered into a collaboration with University of Texas (UT) Southwestern ...

press release

May 5, 2017

Alnylam Announces Amendment to Merck Collaboration to Increase Focus on Development of RNAi Therapeutics; Milestone Payments to Alnylam Could Exceed $120 MillionCAMBRIDGE, Mass. (BUSINESS WIRE) July 6, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has amended its two existing RNAi collaboration agreements with Merck and consolidated the efforts into a single ongoing collaboration. ...

press release

May 5, 2017

Alnylam Pharmaceuticals Reports Second Quarter 2006 Financial Results; Increasing Revenue Drives Improvement in Year over Year FinancialsCAMBRIDGE, Mass. (BUSINESS WIRE) July 26, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter ended June 30, 2006 and company highlights. "Building on our progress in the first quarter, we continued to deliver ...

press release

May 5, 2017

.bwcellpaddingbottom1 {padding bottom: 2.0px} .bwcellpaddingbottom3 {padding bottom: 4.0px} .bwcellpaddingleft0 {padding left: 0.0px} .bwcellpaddingright0 {padding right: 0.0px} .bwcellparagraphmargin {margin bottom: 0px; margin top: 0px} .bwdoublebottomborder {border bottom: double black 2.25pt} .bwlistitemmarginbottom {margin bottom: 10.0px} .bwmarginleft1 {margin left: 30.0px} .bwsinglebottomborder {border bottom: solid black 1.0pt} .bwtablebottommargin {margin bottom: 10.0px} .bwtextaligncenter {text align: center} .bwtextalignleft {text align: left} .bwtextalignright {text align: right} .bwverticalalignbottom {vertical ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 2, 2006 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter ended September 30, 2006 and company highlights. "This was Alnylam's strongest quarter to date as measured by financial performance and revenues, where we've established a solid and sustainable foundation in R&D funding and milestone payments ...